Bicara Therapeutics Inc. Common Stock (BCAX) Stock Score, Valuation & Financial Research

Bicara Therapeutics Inc. Common Stock is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for BCAX

Bicara Therapeutics Inc. Common Stock does not currently have a complete Wall Street Score. The stored market price is USD 18.61. These figures are a research snapshot, not a buy or sell recommendation.

What Bicara Therapeutics Inc. Common Stock does

Bicara Therapeutics Inc., a biopharmaceutical firm in the clinical development phase, is headquartered in Boston, Massachusetts. Established in 2018, the company specializes in creating innovative, dual-action treatments specifically for solid tumors. At the forefront of their pipeline is ficerafusp alfa, a unique antibody designed to tackle solid cancers. This bifunctional therapeutic agent works by simultaneously engaging the epidermal growth factor receptor (EGFR) and binding to human transforming growth factor beta (TGF-b). Bicara Therapeutics operates as a subsidiary of Biocon Limited.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Bicara Therapeutics is a clinical-stage biopharmaceutical company that focuses on the development of bifunctional therapies for solid tumors. As a clinical-stage entity, the company does not currently generate revenue from product sales and relies on capital raises and potential future licensing or collaboration agreements to fund its research and development operations.

Products and services

  • The company's primary product candidate is ficerafusp alfa, a bifunctional fusion protein designed to target solid tumors.

Customer types

Clinical trial patients.

Suppliers, materials and equipment

  • Contract Manufacturing Organizations — The company relies on third-party contract manufacturing organizations for the production of its clinical product candidates; specific supplier names are unnamed. Source

Business relationships and partnerships

  • Biocon Ltd. — The company has a relationship with Biocon Ltd. involving licensed patents related to ficerafusp alfa, which is currently the subject of litigation. Source

Business strengths to evaluate

  • Clinical-stage pipeline focused on bifunctional therapies for solid tumors Source

Business risks and research considerations

  • Ongoing litigation regarding patent inventorship for ficerafusp alfa Source
  • Dependence on third-party manufacturers for clinical supply Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

BCAX financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 18.61
Market capitalization:
1.22B (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -185.36M
Free cash flow:
USD -107.11M
Cash:
USD 96.6M
Total debt:
USD 1.16M
EPS:
USD -3.10

What stands out

  • Free cash flow is USD -107.11M, negative for the stored period.
  • The balance sheet shows USD 96.6M of cash versus USD 1.16M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 95.44M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for BCAX

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can BCAX fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is BCAX likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for BCAX to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of BCAX's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research BCAX

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.